Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report report published on Monday,Benzinga reports. D. Boral Capital currently has a $15.00 price objective on the stock.

Other analysts have also issued reports about the stock. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, November 11th. Chardan Capital reiterated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, February 6th.

Coya Therapeutics Stock Performance

NASDAQ:COYA traded down $0.15 during trading hours on Monday, hitting $6.48. 25,182 shares of the company's stock traded hands, compared to its average volume of 76,376. The stock's fifty day moving average price is $6.27 and its two-hundred day moving average price is $6.46. The firm has a market cap of $108.26 million, a P/E ratio of -9.97 and a beta of 0.31. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its holdings in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Geode Capital Management LLC grew its position in Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock worth $918,000 after acquiring an additional 4,485 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Coya Therapeutics during the 4th quarter valued at $59,000. Finally, Jane Street Group LLC bought a new position in shares of Coya Therapeutics during the 4th quarter valued at $74,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.